10x Genomics Stock Investor Sentiment

TXG Stock  USD 14.86  1.22  7.59%   
Roughly 56% of 10X Genomics' investor base is looking to short. The analysis of overall sentiment of trading 10X Genomics stock suggests that many investors are alarmed at this time. The current market sentiment, together with 10X Genomics' historical and current headlines, can help investors time the market. In addition, many technical investors use 10X Genomics stock news signals to limit their universe of possible portfolio assets.

Panic Vs Confidence

44

 
Panic
 
Confidence
Today, several news technology companies offer sentiment data to assist traders in manufacturing news sentiment indicators for investment decisions. We partner with these technology firms in helping retail investors build forecasting models that use 10X Genomics' input sentiment indicators derived from textual data and news published on major financial information outlets and social sites. These indicators can be used to analyze time-dependent numerical information representing public perception toward 10X Genomics.

10X Historical Sentiment

Although 10X Genomics' investment sentiment alone cannot always predict changes in its future share prices, when combined with other fundamental and technical analysis, a better chance to time the market can be gained. Certain informational and emotional events regarding 10X, such as negative comments on social media and news outlets, may cause fear in the market and push 10X Genomics' investors to sell their holdings. The opposite can also be true when favorable news is released; it may translate into optimism and boost the price of 10X.
  

10X Genomics Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards 10X Genomics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

10X Genomics Historical Investor Sentiment

Investor biases related to 10X Genomics' public news can be used to forecast risks associated with an investment in 10X. The trend in average sentiment can be used to explain how an investor holding 10X can time the market purely based on public headlines and social activities around 10X Genomics. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
10X Genomics' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for 10X Genomics and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average 10X Genomics news discussions. The higher the estimate score, the more favorable the investor's outlook on 10X Genomics.
over six months ago at benzinga.com         
Cathie Woods Ark Invest Sheds 6.4M Worth Of Coinbase Shares Despite Positive Market Movements, Analy...
benzinga news
over six months ago at news.google.com         
Will 10x Genomics Report Negative Earnings Next Week What You Should Know - Yahoo Lifestyle UK
Google News at Macroaxis
over six months ago at news.google.com         
10x Genomics, Inc. Short Interest Update - Defense World
Google News at Macroaxis
over six months ago at news.google.com         
Short Interest in 10x Genomics, Inc. Rises By 24.5 percent - MarketBeat
Google News at Macroaxis
over six months ago at news.google.com         
10x Genomics, Inc. Shares Bought by Vanguard Group Inc. - MarketBeat
Google News at Macroaxis
over six months ago at finance.yahoo.com         
10x Genomics Commercially Launches Visium HD Spatial Gene Expression Assay
Yahoo News
over six months ago at news.google.com         
10x Genomics, Inc. Revenue Breakdown NASDAQTXG TradingView - TradingView
Google News at Macroaxis
over six months ago at news.google.com         
Citigroup Inc. Has 452000 Stock Position in 10x Genomics, Inc. - Defense World
Google News at Macroaxis
over six months ago at news.google.com         
Handelsinvest Investeringsforvaltning Purchases Shares of 6066 10x Genomics, Inc. - Defense World
Google News at Macroaxis
over six months ago at finance.yahoo.com         
10x Genomics Expands Xenium Menu with Multi-Modal Cell Segmentation Kit and Immuno-Oncology Gene Pan...
Yahoo News
over six months ago at finance.yahoo.com         
Acquisition by Justin McAnear of 53312 shares of 10X Genomics subject to Rule 16b-3
Yahoo News
over six months ago at bizjournals.com         
NanoString bankruptcy illustrates how patent disputes have become a biotech battleground
bizjournals News
over six months ago at news.google.com         
10x Genomics, Inc. Shares Sold by Teachers Retirement System of The State of Kentucky - Defense Worl...
Google News at Macroaxis
over six months ago at benzinga.com         
Disposition of 1086 shares by Serge Saxonov of 10X Genomics subject to Rule 16b-3
benzinga news
over six months ago at benzinga.com         
Johnson Fistel Announces Investigation of 10x Genomics for Potential Securities Law Violations
benzinga news
Far too much social signal, news, headlines, and media speculation about 10X Genomics that are available to investors today. That information is available publicly through 10X media outlets and privately through word of mouth or via 10X internal channels. However, regardless of the origin, that massive amount of 10X data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of 10X Genomics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of 10X Genomics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to 10X Genomics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive 10X Genomics alpha.

10X Genomics Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
10x Genomics Inc Shares Down 5.27 percent on Sep 25
09/25/2024
2
10x Genomics Expected to Beat Earnings Estimates Can the Stock Move Higher
10/22/2024
3
Earnings Update 10x Genomics, Inc. Just Reported And Analysts Are Trimming Their Forecasts
11/01/2024
4
Sumitomo Mitsui Trust Groups Strategic Acquisition in 10x Genomics Inc
11/05/2024
5
Disposition of 534 shares by Serge Saxonov of 10X Genomics at 55.064 subject to Rule 16b-3
11/12/2024
6
10X Genomics SWOT analysis genomics firms stock faces headwinds, eyes recovery
11/13/2024
7
Al Gores Strategic Moves in Q3 2024 Spotlight on Agilent Technologies with a 2.1 percent Portfolio Impact
11/14/2024
8
Disposition of 1850 shares by Serge Saxonov of 10X Genomics subject to Rule 16b-3
11/21/2024
9
10x genomics CEO Serge Saxonov sells 91,612 in stock
11/25/2024
10
10x Genomics Inc Stock Price Down 3.81 percent on Dec 5
12/05/2024
11
Disposition of 441 shares by Justin McAnear of 10X Genomics at 55.0641 subject to Rule 16b-3
12/06/2024
12
46,029 Shares in 10x Genomics, Inc. Purchased by Weiss Asset Management LP - MarketBeat
12/09/2024

Complementary Tools for 10X Stock analysis

When running 10X Genomics' price analysis, check to measure 10X Genomics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy 10X Genomics is operating at the current time. Most of 10X Genomics' value examination focuses on studying past and present price action to predict the probability of 10X Genomics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move 10X Genomics' price. Additionally, you may evaluate how the addition of 10X Genomics to your portfolios can decrease your overall portfolio volatility.
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Sectors
List of equity sectors categorizing publicly traded companies based on their primary business activities
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency